Marquette Asset Management, LLC
Position in ENGN — enGene Therapeutics Inc.
CIK 1395067
MINNEAPOLIS, MN
Position in ENGN
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$260,444
New position
Shares Held
150,546
first reported quarter
Ownership
0.225%
of shares outstanding
% of Portfolio
0.58%
of 13F equity value
Holder Rank
#1
of 1 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Marquette Asset Management, LLC holds $1,528,077 across 29 Biotechnology names. ENGN ranks #2 (17.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BCYC |
Bicycle Therapeutics PLC
|
72,854 | $308,900 | |
| 2 | ENGN |
enGene Therapeutics Inc.
This page
|
150,546 | $260,444 | |
| 3 | NKTX |
Nkarta, Inc.
|
75,071 | $212,450 | |
| 4 | PLRX |
Pliant Therapeutics, Inc.
|
174,500 | $198,930 | |
| 5 | FULC |
Fulcrum Therapeutics, Inc.
|
38,552 | $141,100 | |
| 6 | ZNTL |
Zentalis Pharmaceuticals, Inc.
|
28,973 | $140,519 | |
| 7 | SEER |
Seer, Inc.
|
61,816 | $102,614 | |
| 8 | MGX |
Metagenomi Therapeutics, Inc.
|
72,121 | $85,823 |
All Filings in ENGN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $260,444 | 150,546 | Shares | Sole | 2026-07-09 | |
| No filing history on record for this holder in this stock. | ||||||